2024-12-05 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Review

This report analyzes Teladoc Health Inc. (TDOC), a telehealth company providing virtual care services.

**1. Performance Comparison & Divergence:**

Teladoc's cumulative return of -61.70% significantly underperforms the S&P 500 (VOO) with a return of 128.32%.  The difference is a substantial -180.02%.  The provided relative divergence of 0.6 indicates that TDOC's performance is near the lower end of its historical range relative to the S&P 500.  The high volatility highlighted by the maximum and minimum divergence values (728.8 and -195.3 respectively) shows a highly variable relationship with the S&P 500.  The provided Alpha values of 0.0 suggest that the stock's performance has not consistently outperformed or underperformed the market in these historical periods. The high Beta values indicate significant market sensitivity.


**2. Recent Price Movement:**

* **Closing Price:** $10.95
* **5-Day Moving Average:** $11.45
* **20-Day Moving Average:** $10.09
* **60-Day Moving Average:** $9.25

The price is slightly below the 5-day moving average, suggesting recent downward pressure.  It is above the 20-day and 60-day moving averages indicating a potential short-term recovery.  The relatively small difference between the last market price (10.97) and closing price suggests a stable day in the market.


**3. Technical Indicators & Expected Return:**

* **RSI:** 59.40 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 1.46 (Positive, suggesting bullish momentum)
* **Relative Divergence Change (20-day):** nan (-) Indicates recent downward trend.  Further analysis is required, as the `nan` value suggests missing data.
* **Expected Return:** 0.0%  This indicates that, based on the provided information, there's no expected outperformance compared to the S&P 500 over the long term (2+ years) with a buy-and-hold strategy.  This is likely a conservative estimate given the volatility and historical underperformance of TDOC.


**4. Recent Earnings Analysis:**

The most recent quarterly results show a consistent trend of negative EPS, although there's some slight fluctuation.  Revenue remains relatively stable around $0.64-$0.66 Billion across the reported quarters. There is no information provided about the expectations against which to judge "beats" or "misses."

| Date       | EPS     | Revenue      | Revenue Change | EPS Change  |
|------------|---------|--------------|-----------------|-------------|
| 2024-10-31 | -$0.19  | $0.64 B      |                 |             |
| 2024-08-01 | -$4.92  | $0.64 B      | $0.00 B         | -$4.73       |
| 2024-04-26 | -$0.49  | $0.65 B      | $0.01 B         | $4.43        |
| 2023-10-27 | -$0.35  | $0.66 B      | $0.02 B         | $0.14        |
| 2024-10-31 | -$0.35  | $0.66 B      | $0.00 B         | $0.00       |


**5. Financial Information Analysis:**

Revenue has remained relatively flat over the past year, showing minimal growth. Profit margins are consistently high (70-72%), suggesting efficient operations despite negative EPS.  Equity shows significant fluctuation, and ROE is consistently negative, indicating the company is not generating returns on its equity. This warrants further investigation into the underlying reasons for the negative ROE, even with the high profit margins.

**6. News and Recent Issues:**

No information on recent earnings news (within the last 2 days), market outlook, or analyst opinions is provided.  This critical information gap prevents a complete assessment of the current market sentiment towards TDOC.


**7. Overall Analysis:**

Teladoc Health is currently underperforming the S&P 500 significantly.  While revenue remains relatively stable, the company is reporting negative EPS and negative ROE.  Technical indicators present a mixed picture.  The lack of recent news and analyst sentiment makes it difficult to gauge the short-term outlook.  The high volatility and historical performance indicate a high-risk investment, and the provided 0% expected return strongly suggests caution. Before investing, it is crucial to access and analyze missing information, such as analyst reports and recent news, as well as a deeper dive into the reasons for negative ROE despite healthy profit margins.  The high Beta suggests significant market sensitivity; therefore, broader market trends will have a substantial impact on TDOC's performance.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  The analysis is based solely on the provided data and may not reflect the complete picture.  Conduct thorough independent research before making any investment decisions.
